Results 71 to 80 of about 1,100,787 (194)

Economic Burden of Chronic Lymphocytic Leukaemia in Australia

European Journal of Haematology, EarlyView.
ABSTRACT Background The treatment landscape for chronic lymphocytic leukaemia (CLL) has transformed over the past decade. This study aimed to estimate the healthcare costs and health burden associated with CLL in Australia. Methods A Markov model was developed to simulate the lifetime healthcare costs and health outcomes associated with CLL in ...
Lan Gao, Dieu Nguyen, Victoria White, Patricia M. Livingston, Chan Y. Cheah   +4 more
wiley   +1 more source

Pathophysiology and emerging treatments for dermographic, cholinergic and cold urticaria

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This review illustrates key proposed mast cell‐mediated activation pathways in dermographic, cholinergic and cold urticaria, highlighting IgE‐dependent and ‐independent mechanisms. These pathways are increasingly targeted by emerging drugs, aiming to interrupt mast cell activation and mediator release, offering more precise, mechanism‐based treatment ...
Mojca Bizjak‐Suran, Matjaž Fležar, Manuel Pedro Pereira   +2 more
wiley   +1 more source

Bruton Tyrosine Kinase Inhibitors

The Cancer Journal, 2019
Abstract Bruton tyrosine kinase (BTK) is a nonreceptor tyrosine kinase that plays a central role in the signal transduction of the B-cell antigen receptor and other cell surface receptors, both in normal and malignant B lymphocytes. B-cell antigen receptor signaling is activated in secondary lymphatic organs and drives the proliferation of ...
openaire   +3 more sources

Protein recruitment to receptor tyrosine kinase-mediated early signalling complexes. [PDF]

, 2007
Receptor tyrosine kinase (RTK) signalling regulates the activation of numerous cellular processes in response to various external stimuli. Spatio-temporal regulation of protein recruitment to activated tyrosine kinase receptors is important for the ...
Schller, A.C.
core  

Management of chronic urticaria: Current status and future prospect

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Chronic urticaria is driven by mast cell activation through autoimmune, inflammatory, and neuroimmune pathways. A structured approach combining diagnosis, patient‐reported outcomes, stepwise therapy, treatment optimization, monitoring and emerging targeted agents may improve disease control and enable more personalized management.
Andaç Salman, Mona Al‐Ahmad, Maryam Al‐Nesf, Chia‐Yu Chu, Luis Felipe Ensina, Ana M. Gimenez‐Arnau, Margarida Gonçalo, Clive Grattan, Michihiro Hide, Pavel Kolkhir, Martin Metz, Iman Nasr, Romi Saini, Simon Francis Thomsen, Torsten Zuberbier, Emek Kocaturk   +15 more
wiley   +1 more source

Pirtobrutinib in Richter syndrome: Outcomes from the named patient programme in Italy

British Journal of Haematology, EarlyView.
Isacco Ferrarini, Daniela Estefania Banegas, Andrea Bernardelli, Alessia Moioli, Francesca Maria Quaglia, Ester Lovato, Anna Maria Frustaci, Massimiliano Postorino, Davide Facchinelli, Monica Tani, Francesca Cibien, Chandrakala Toldo, Elisa Lucchini, Roberto Marasca, Marzia Varettoni, Chiara Rusconi, Lucia Farina, Andrea Visentin, Riccardo Moia, Carlo Visco   +19 more
wiley   +1 more source

Reactogenicity and Immunogenicity of RSV Vaccines in Immunocompromised Individuals With Hematological Malignancies

Transplant Infectious Disease, EarlyView.
In adults with hematologic malignancies, RSV vaccination was safe and induced antibody and T‐cell responses. However, antibody levels were lower and declined more rapidly than in healthy controls. While early immune responses were evident, reduced magnitude and durability of protection suggest the need for optimized vaccination strategies in this high ...
Alisse Hannaford, Zoe Swank, Simon D. van Haren, Natalie Izaguirre, Caitlin Syphurs, Zhou Lan, Bridget Yates, Urwah Kanwal, Grace Valentine, Ella Woehl, David Regan, Hannah Levine, Alexandra Tong, Maria Shehata, Fathia Oladipupo, Colleen Sedney, Kevin Ryff, Sanya Thomas, Joann Diray‐Arce, Xiaofang Li, Kimberly A. Dufresne, Lindsey A. Parisi, Aidan Eustace, Louise Hansen, David R. Walt, Ofer Levy, Amar Kelkar, Robert J. Soiffer, Vincent T. Ho, Lindsey R. Baden, Nicolas C. Issa, Ann E. Woolley, Amy C. Sherman   +32 more
wiley   +1 more source

Ets-2 is a target for an Akt (protein kinase B)/Jun N-terminal kinase signaling pathway in macrophages of motheaten-viable mutant mice [PDF]

, 2000
The transcription factor ets-2 was phosphorylated at residue threonine 72 in a colony-stimulating factor 1 (CSF-1)- and mitogen-activated protein kinase-independent manner in macrophages isolated from motheaten-viable (me-v) mice.
Forsthoefel, David, Ostrowski, M C, Hartman, M, Schaffner, A E, Smith, James L., Hume, D A, Smith, J L, Ostrowski, Michael C., Wei, G, Hofmeister, Joseph K., Hofmeister, J K, Schaffner, Alicia E., Wei, Guo, Hume, David A., Hartman, Matthew, Hartman, Matthew Hartman, Forsthoefel, D   +16 more
core   +1 more source

Visible‐Light‐Initiated, Nickel‐Catalyzed Aminocarbonylation of Alkynyl Iodides to 2‐Ynamides

Advanced Synthesis &Catalysis, Volume 368, Issue 19, 1 October 2026.
Visible light initiates a nickel‐catalyzed aminocarbonylation of alkynyl iodides, enabling the synthesis of 2‐ynamides under low carbon monoxide pressure. The method operates under mild conditions, tolerates a broad substrate scope, and proceeds through a light‐triggered nickel(I)/nickel(III) carbonylative pathway.
Michael Weiser, Alexander Frischauf, Berthold Stöger, Ertan Turhan, Dennis Kurzbach, Katharina Bica‐Schröder   +5 more
wiley   +1 more source

Bosutinib: a SRC–ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia

, 2013
Fuad El Rassi, Hanna Jean KhouryDivision of Hematology, Department of Hematology and Medical Oncology, the Winship Cancer Institute at Emory University, Atlanta, Georgia, USAAbstract: Bosutinib is one of five tyrosine kinase inhibitors commercially ...
Khoury HJ, El Rassi F
core